Filing Overview
Adagio Therapeutics, Inc. filed a Form 8-K dated June 17, 2022, under Item 5.02. The filing concerns a board resignation. The submitted metadata identifies Invivyd, Inc., but the filing itself identifies the registrant as Adagio Therapeutics, Inc., trading under the symbol ADGI.
Business Context and Reporting Period
The filing was signed on June 21, 2022, and reports an event occurring on June 17, 2022. Adagio Therapeutics is incorporated in Delaware and was listed on The Nasdaq Stock Market.
Financial and Operating Metrics
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Change
- Anand Shah, M.D. notified the company of his decision to resign from its board of directors and all board committees.
- The resignation was to become effective immediately following adjournment of the company’s 2022 annual meeting of stockholders, scheduled for June 22, 2022.
Guidance, Outlook, Risks, and Unusual Items
The filing does not provide financial guidance, operational outlook, management commentary, risk updates, contingencies, or unusual financial items. No reason for the resignation was disclosed.
Investor Verification Points
- Confirm the discrepancy between the request metadata identifying Invivyd, Inc. and the filing identifying Adagio Therapeutics, Inc.
- Verify completion of the June 22, 2022 annual meeting and the effective date of Dr. Shah’s resignation.
- Review subsequent filings for board composition, committee membership, and any disclosed reason or related governance changes.